+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 7 Actively Recruiting clinical trials

P

Actively Recruiting

Researchers are evaluating the effects of elecoglipron compared with a placebo in adults with chronic kidney disease CKD, including those with and without type 2 diabetes mellitus T2DM. This Phase III, randomized, double-blind, placebo-controlled study includes participants who are receiving standard care treatments for CKD, including the SGLT2 inhibitor dapagliflozin. The study aims to determine whether elecoglipron can reduce the risk of kidney function decline, end-stage kidney disease, and mortality. Participants will be randomly assigned to receive either elecoglipron tablets or matching placebo tablets once daily. The study is multicenter and involves parallel groups. The treatment period and evaluation are event-driven and may last up to 4.5 years. Both study groups will continue their background therapies for CKD alongside the study medication or placebo. During the study, participants will be monitored regularly to assess kidney function, cardiovascular events, and overall health outcomes, including mortality. Researchers will measure sustained declines in estimated glomerular filtration rate eGFR, occurrence of end-stage kidney disease, cardiovascular death, heart failure hospitalizations, and other related outcomes. The study includes safety monitoring throughout the trial, which is expected to last until October 2030, with participant involvement potentially extending up to 4.5 years.

Age: 18Years +All GendersPhase 3
715 locations
E

Actively Recruiting

Researchers are evaluating whether tenecteplase helps adults recover from an acute ischemic stroke when given more than 4.5 hours after the person was last seen well. This study focuses on people who had a stroke caused by a clot blocking a brain blood vessel and have imaging showing brain tissue that can still be saved. Participants are excluded if they are planned for a procedure to remove the clot. Participants are randomly placed into two groups. One group receives a single intravenous injection of tenecteplase, while the other group receives standard medical care. The trial compares these treatments to see if tenecteplase improves recovery when given later than the usual 4.5-hour window after stroke onset. Participants stay in the study for about three months, including roughly one week in the hospital. They undergo seven clinical visits or exams, with the last two likely done remotely from home. Doctors assess recovery using a scale that measures disability and dependence in daily life. They also monitor health and any side effects to compare outcomes between the two groups.

Age: 18Years +All GendersPhase 3
257 locations
M

Actively Recruiting

This research aims to understand acute malnutrition in infants younger than 6 months admitted to pediatric or perinatology wards in hospitals across Indonesia. The study will observe how common acute malnutrition is in this age group and investigate the outcomes of nutrition therapy, including recovery, growth improvement, complications, and death. It also seeks to identify factors linked to successful nutrition treatment based on the 2023 WHO criteria. The study is observational and will not provide experimental treatments. Instead, it will collect detailed measurements of infants weight, length, head circumference, and mid-upper arm circumference at baseline, day 3, day 7, and weekly until hospital discharge. Information about birth history, feeding, illnesses, and nutrition therapy provided by treating doctors will be recorded. Data will be securely stored in a shared electronic database to ensure consistency across multiple hospitals participating in the network. Participants will be infants under 6 months diagnosed with acute malnutrition. Researchers will gather clinical data, anthropometric measurements, feeding details, and lab results during hospital stay. The study will monitor nutritional status changes up to 24 weeks or until discharge and track outcomes such as mortality. Results will help develop evidence-based feeding guidelines and improve clinical care for malnourished infants in Indonesia.

Age: 1Day - 6MonthsAll Genders
16 locations
R

Actively Recruiting

Researchers are evaluating the real-world effectiveness and safety of Nebilet4 nebivolol in adults with hypertension across seven Asian countries. This multinational, multicenter, observational, and prospective study aims to assess blood pressure changes, treatment adherence, quality of life, prescription patterns, and cardiovascular outcomes over up to three years. The study also compares Nebilet4 used alone versus in combination therapy and investigates the relationship between home and office blood pressure measurements. Participants include about 5,000 adults newly diagnosed with or having uncontrolled hypertension who have recently started Nebilet4 or been on it no more than two weeks. Patients are followed regularly for 12, 24, and 36 months, with blood pressure measured at each visit and home readings encouraged. The study collects data on medication dosing and frequency, adherence, and cardiovascular risk factors, while monitoring major adverse cardiac events such as heart attack, stroke, and cardiovascular death. During the study, participants complete questionnaires to assess quality of life and medication adherence every few months. Data are recorded through an electronic system ensuring consistency across sites. Researchers evaluate changes in systolic and diastolic blood pressure and the proportion achieving target blood pressure goals. Safety and any adverse events are documented, with follow-up visits extending up to three years to provide insights into the long-term management of hypertension with Nebilet4.

Age: 18Years - 100YearsAll Genders
49 locations
S

Actively Recruiting

Researchers are studying the effects of synbiotic supplementation on patients with Metabolic Dysfunction-Associated Fatty Liver Disease MAFLD, a type of fatty liver condition linked to metabolic issues like obesity and diabetes. This research aims to see if synbiotics can change metabolic profiles, insulin levels, inflammatory marker TNF-alpha, and gut microbiota in these patients. The study is designed as a randomized controlled trial to analyze these effects in adults aged 25 to 55 years. Participants are divided into two groups one receives RILLUS, a synbiotic supplement containing specific probiotic bacteria and prebiotic fibers, while the other receives a placebo that looks similar but lacks the live bacteria. Both groups will take two tablets daily for 12 weeks. Hospital visits for control and follow-up occur every 28 days over about four months. Participants will also keep logs to track supplement intake and food consumption. Throughout the study, participants will undergo various assessments including blood tests for hematology, metabolic profiles, insulin, TNF-alpha, and C-reactive protein at three months. Gut microbiota diversity will be evaluated at four months. The researchers will monitor compliance and collect data to understand how synbiotic treatment may influence these health markers. The total study duration for each participant is about four months, including supplementation and follow-up periods.

Age: 25Years - 55YearsAll GendersPhase Not Applicable
1 location
S

Actively Recruiting

Researchers are evaluating the effects of low-level tragus stimulation LLTS on heart function in patients who have experienced ST-segment Elevation Myocardial Infarction STEMI and are undergoing primary percutaneous coronary intervention PPCI. This study aims to understand if LLTS can improve measures such as left ventricular ejection fraction, wall motion score index, and diastolic function compared to a sham control. The safety of LLTS in this setting is also being assessed. Participants will be randomly assigned to one of two groups the treatment group receiving LLTS via the Parasym device on the left tragus for 60 minutes, or the sham control group where the Parasym device is implanted without active stimulation for the same duration. Both groups will undergo transthoracic echocardiography examinations before and after PPCI to assess heart function. During the study, participants will have echocardiographic measurements taken before PPCI, one day after PPCI, and 30 days after PPCI to monitor changes in left ventricular ejection fraction, wall motion score index, and diastolic function. The study will last through these time points to evaluate both the effect and safety of LLTS treatment in STEMI patients.

Age: 18Years - 75YearsAll GendersPhase Not Applicable
1 location
A

Actively Recruiting

Researchers are evaluating a new Morphology-Voltage-P-wave Score MVP Score to help diagnose left ventricular diastolic dysfunction in people with hypertension. This observational study collects detailed data including demographics, clinical signs, laboratory tests, and heart ultrasound echocardiography results to validate the usefulness of the MVP Score in identifying heart dysfunction related to high blood pressure. Participants will have their 12-lead electrocardiogram ECG reviewed to calculate the MVP Score, which will then be compared with results from transthoracic echocardiography assessing heart function. The study groups include patients with and without left ventricular diastolic dysfunction, based on these assessments. During the study, investigators will gather information from medical records and perform ECG and echocardiography evaluations. They will analyze the data using statistical software to confirm the MVP Scores accuracy in diagnosing diastolic dysfunction. The main outcome measured is the presence of diastolic dysfunction within one week of assessment. Participation involves one-time diagnostic tests and data collection with no treatment interventions.

Age: 18Years - 70YearsAll Genders
1 location